Samsung Biologics, 154 Billion KRW Contract for European Biopharmaceutical Contract Manufacturing
[Asia Economy Reporter Ji Yeon-jin] Samsung Biologics announced on the 25th that it has signed a letter of intent for a contract worth 154 billion KRW for contract manufacturing of biopharmaceuticals with a European pharmaceutical company. The contract period is from today until August 31.
Hot Picks Today
!["Stock Set to Double: This Company Smiles Every Time a Data Center Is Built [Click e-Stock]"](https://cwcontent.asiae.co.kr/asiaresize/93/2026050416112750184_1777878687.jpg)
"Stock Set to Double: This Company Smiles Every...
- "Continuous Groundwater Pumping Causes Mexico City to Sink 24cm Annually... 'Gia...
- “She Shouted, ‘The Rope Isn’t Tied!’... Chinese Woman Falls from 168m Cliff ...
- Samsung Electronics Officially Decides to Withdraw Some Home Appliance Businesse...
- "Prime Minister in Underwear?"... Italy's Meloni Posts Herself to Warn of Deepfa...
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
